Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Peuskens

Showing results (11-20 of 75) with videos related to

Pageof 8
Sort By:
International Clinical Psychopharmacology|April 7, 2007
Metabolic control in patients with schizophrenia treated with amisulpride or olanzapineJoseph Peuskens, Marc De Hert, Ann Mortimer, et al.
Schizophrenia Research|July 17, 2007
Analysis of resolution criteria in patients with schizophrenia treated with olanzapine for an acute psychotic episodeJoseph Peuskens, Leonard Kaufman, Betty Van Vleymen
International Clinical Psychopharmacology|April 13, 2004
A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophreniaAnn Mortimer, Stephen Martin, Henri Lôo, et al.
Early Intervention in Psychiatry|January 25, 2013
Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia Treatment Adherence Registry (e-STAR) and Trial for the Initiation and Maintenance Of REmission in Schizophrenia with risperidone (TIMORES)Vincent Dubois, Joseph Peuskens, Paul Geerts, et al.
Bipolar Disorders|June 9, 2009
Ultra-brief pulse ECT in bipolar and unipolar depressive disorder: differences in speed of responsePascal Sienaert, Kristof Vansteelandt, Koen Demyttenaere, et al.
International Clinical Psychopharmacology|March 11, 2010
Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate: post-hoc analysis of data from a randomized withdrawal, placebo-controlled studyJoseph Peuskens, Jitendra K Trivedi, Martin Brecher, et al.
The Journal of ECT|May 22, 2009
Predictors of patient satisfaction after ultrabrief bifrontal and unilateral electroconvulsive therapies for major depressionPascal A Sienaert, Kristof Vansteelandt, Koen Demyttenaere, et al.
European Archives of Psychiatry and Clinical Neuroscience|September 8, 2010
Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidoneMarc De Hert, Aurélia Mittoux, Yuan He, et al.
The International Journal of Eating Disorders|March 30, 2004
Sleep variables in anorexia nervosa: evolution with weight restorationGuido Pieters, Paul Theys, Walter Vandereycken, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 5, 2002
Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind studyDaniel Sechter, Joseph Peuskens, Odile Fleurot, et al.
Pageof 8

Showing results (11-20 of 75) with videos related to

Sort By:
Pageof 8
International Clinical Psychopharmacology|April 7, 2007
Metabolic control in patients with schizophrenia treated with amisulpride or olanzapineJoseph Peuskens, Marc De Hert, Ann Mortimer, et al.
Schizophrenia Research|July 17, 2007
Analysis of resolution criteria in patients with schizophrenia treated with olanzapine for an acute psychotic episodeJoseph Peuskens, Leonard Kaufman, Betty Van Vleymen
International Clinical Psychopharmacology|April 13, 2004
A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophreniaAnn Mortimer, Stephen Martin, Henri Lôo, et al.
Early Intervention in Psychiatry|January 25, 2013
Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia Treatment Adherence Registry (e-STAR) and Trial for the Initiation and Maintenance Of REmission in Schizophrenia with risperidone (TIMORES)Vincent Dubois, Joseph Peuskens, Paul Geerts, et al.
Bipolar Disorders|June 9, 2009
Ultra-brief pulse ECT in bipolar and unipolar depressive disorder: differences in speed of responsePascal Sienaert, Kristof Vansteelandt, Koen Demyttenaere, et al.
International Clinical Psychopharmacology|March 11, 2010
Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate: post-hoc analysis of data from a randomized withdrawal, placebo-controlled studyJoseph Peuskens, Jitendra K Trivedi, Martin Brecher, et al.
The Journal of ECT|May 22, 2009
Predictors of patient satisfaction after ultrabrief bifrontal and unilateral electroconvulsive therapies for major depressionPascal A Sienaert, Kristof Vansteelandt, Koen Demyttenaere, et al.
European Archives of Psychiatry and Clinical Neuroscience|September 8, 2010
Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidoneMarc De Hert, Aurélia Mittoux, Yuan He, et al.
The International Journal of Eating Disorders|March 30, 2004
Sleep variables in anorexia nervosa: evolution with weight restorationGuido Pieters, Paul Theys, Walter Vandereycken, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 5, 2002
Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind studyDaniel Sechter, Joseph Peuskens, Odile Fleurot, et al.
Pageof 8